Impact of influenza vaccination in patients with chronic liver disease

  • Härmälä S & al.
  • BMJ Open
  • 6 Sep 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • This study suggests that in patients with chronic liver disease, the influenza vaccine may not protect against all-cause mortality.
  • However, it triggers an effective antibody response and may reduce the risk for all-cause hospitalisation.

Why this matters

  • Patients with liver disease are frequently admitted to hospitals with infection often the trigger.
  • Although influenza vaccination can effectively prevent infection in healthy and elderly, it is often perceived less beneficial in patients with liver disease.

Study design

  • Meta-analysis included 12 studies identified after a search on MEDLINE, EMBASE, PubMed and CENTRAL databases.
  • Outcome: all-cause hospitalisation and mortality, cause-specific hospitalisation and mortality and serological vaccine response.
  • Funding: UK Biotechnology and Biological Sciences Research Council.

Key results

  • Vaccination was associated with a reduction in the risk for hospital admission in patients with viral liver disease with a drop from 205/1000 to 149/1000 patients (risk difference [RD], −0.06; 95% CI, −0.07 to −0.04).
  • The risk for hospitalisation was lower in patients vaccinated with hepatitis B virus vs unvaccinated patients (risk ratio [RR], 0.73; 95% CI, 0.66-0.80).
  • Vaccinated vs unvaccinated patients had no less risk for death during:
    • influenza season (pooled random effects RR, 0.80 [95% CI, 0.43-1.50]; RD, −0.001 [95% CI, −0.01 to 0.01]; I2=33.00%; P=0.23); and
    • entire year (pooled random effects RR, 0.41 [95% CI, 0.11-1.52]; RD, −0.06 [95% CI, −0.08 to 0.04]; I2=94.00%).
  • No effect against all-cause or cause-specific mortality or cause-specific hospitalisation was observed.

Limitations

  • Publication bias.
  • Inclusion of non-randomised studies.